Revolo Announces Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference
07 Agosto 2024 - 7:45AM
Revolo Biotherapeutics Limited (“Revolo”) today announced that
President and Chief Executive Officer, Woody Bryan, Ph.D., will
participate in a fireside chat on Wednesday, August 14 at 11:30
a.m. ET at Canaccord Genuity’s 44th Annual Growth Conference being
held in Boston at the InterContinental from August 13-15, 2024.
Mr. Bryan and other members of Revolo’s leadership team will be
available for one-one-one meetings. If interested in a meeting,
please connect with Revolo via the Canaccord Genuity meeting
platform.
About Revolo BiotherapeuticsRevolo is
developing therapies that work upstream in the immune cascade for
the treatment of autoimmune and allergic diseases, without the
immune system suppression seen with current therapies. Its two drug
candidates, ‘1805 and ‘1104, a protein and a peptide respectively,
restore immune homeostasis to prevent the chronic pro-inflammatory
immune response that results in autoimmune or allergic disease. The
disease-agnostic mechanism of action of Revolo Biotherapeutic’s
assets provides a potential platform for the development of
treatments for multiple autoimmune and allergic diseases.For
further information, please visit www.revolobio.com.
Company ContactWoody Bryan, Ph.D.President and
CEOwbryan@revolobio.com
Media ContactMichael RubensteinLifeSci
Communications+1 561-289-7981mrubenstein@lifescicomms.com